The hypothesis that CXCR4 contributes to the resistance of AML cells to signal transduction inhibitor- and chemotherapy-induced apoptosis is currently being tested in a series of Phase I/II studies in humans 58. Here, CXCR4 is linked to acute myeloid leukemia.